New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
Activate Your Account with an access code or Create a New Account
A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma
The purpose of this research study is to find out whether adding an experimental vaccine
called rindopepimut (also known as CDX-110) to the commonly used drug bevacizumab can
improve progression free survival (slowing the growth of tumors) of patients with relapsed
EGFRvIII positive glioblastoma.
Principal Investigator
- Gordon Li, MD
Stanford Investigator(s)
- Seema Nagpal, MD